Online appendix for: Sex differences in the prediction of type 2 diabetes by inflammatory markers: Results from the MONICA/KORA Augsburg case-cohort study, 1984-2002 by Thorand et al.

Table I. Weighted means (standard error) and proportions of demographic and clinical characteristics for subjects with and without incident type 2 diabetes mellitus.

|  | Men |  |  | Women |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Characteristics | Cases | Non-cases | $P$ value | Cases | Non-cases | $P$ value |
| Number | 305 | 889 | - | 222 | 809 | - |
| Age (years)* | 56.1 (0.6) | 51.7 (0.4) | < 0.001 | 56.2 (0.6) | 51.7 (0.4) | < 0.001 |
| Education < 12 years (\%) | 74.8 | 65.8 | 0.003 | 92.8 | 83.7 | < 0.001 |
| Body mass index ( $\left.\mathrm{kg} / \mathrm{m}^{2}\right)^{*}$ | 29.6 (0.2) | 27.1 (0.1) | < 0.001 | 30.9 (0.3) | 26.4 (0.2) | < 0.001 |
| Waist circumference (cm) ${ }^{\text {*, } \ddagger}$ | 103.5 (0.8) | 95.4 (0.4) | < 0.001 | 94.3 (1.0) | 82.6 (0.5) | < 0.001 |
| Waist-hip-ratio*, $\ddagger$ | 0.966 (0.004) | 0.926 (0.003) | < 0.001 | 0.857 (0.006) | 0.804 (0.003) | < 0.001 |
| Systolic BP (mm Hg)* | 142.5 (1.0) | 134.6 (0.7) | < 0.001 | 142.3 (1.3) | 130.6 (0.7) | < 0.001 |
| Diastolic BP ( mm Hg )* | 85.4 (0.7) | 83.3 (0.4) | 0.008 | 84.5 (0.8) | 79.6 (0.4) | < 0.001 |
| Use of antihypertensive medication (\%) | 23.9 | 14.0 | < 0.001 | 40.5 | 13.8 | < 0.001 |
| Actual Hypertension (\%) | 66.2 | 43.6 | < 0.001 | 69.4 | 36.0 | < 0.001 |
| Ratio TC/HDL-C* | 6.0 (0.1) | 5.0 (0.1) | < 0.001 | 5.0 (0.1) | 3.9 (0.04) | < 0.001 |
| Use of lipid lowering medication (\%) | 6.2 | 3.0 | 0.04 | 2.7 | 1.9 | 0.52 |
| Low level of physical activity (\%) | 65.6 | 57.3 | 0.01 | 75.7 | 61.4 | < 0.001 |
| Smoking status (\%) |  |  | 0.02 |  |  | 0.40 |
| Never smoker | 22.6 | 30.3 |  | 67.1 | 64.7 |  |
| Former smoker | 42.0 | 40.2 |  | 17.6 | 16.3 |  |
| Current smoker | 35.4 | 29.5 |  | 15.3 | 19.0 |  |

Table I. continued:

| Alcohol intake (\%) | 0.10 |  |  |  |  | 0.02 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $0 \mathrm{~g} /$ day | 20.0 | 15.9 |  | 51.8 | 41.3 |  |
| $0.1-39.9 / 19.9$ g/day ${ }^{\S}$ | 44.6 | 51.4 |  | 32.9 | 37.3 |  |
| $\geq 40 / 20 \mathrm{~g} / \mathrm{day}^{\S}$ | 35.4 | 32.7 |  | 15.3 | 21.4 |  |
| Parental history of DM (\%) |  |  | 0.005 |  |  | $<0.001$ |
| Negative | 47.2 | 58.2 |  | 41.9 | 61.2 |  |
| Positive | 24.6 | 18.4 |  | 33.3 | 21.1 |  |
| Unknown | 28.2 | 23.4 |  | 24.8 | 17.8 |  |
| Prevalent stroke (\%) | 1.6 | 1.6 | 0.96 | 1.8 | 0.4 | 0.14 |
| Prevalent MI (\%) | 6.9 | 3.3 | 0.02 | 2.7 | 0.9 | 0.11 |
| Angina pectoris (\%) | 6.9 | 4.0 | 0.07 | 5.9 | 4.8 | 0.54 |
| Current HRT (\%) ${ }^{\text {I }}$ |  |  | - | 8.2 | 11.7 | 0.19 |
| Current use of OC (\%) ${ }^{\text {\# }}$ |  |  | - | 7.7 | 15.3 | 0.08 |
| CRP (mg/l) ${ }^{\dagger}$ | 2.1 (1.1) | 1.4 (1.0) | < 0.001 | 3.3 (1.1) | 1.3 (1.0) | < 0.001 |
| $\mathrm{IL}-6(\mathrm{pg} / \mathrm{ml})^{\dagger}$ | 2.9 (1.1) | 2.1 (1.0) | < 0.001 | 3.2 (1.1) | 1.9 (1.0) | < 0.001 |

* arithmetic mean (SE); ${ }^{\dagger}$ geometric mean (antilog of SE); ${ }^{\ddagger}$ only for survey 2 and 3
$\S$ for men 0.1 - $39.9 \mathrm{~g} /$ day and $\geq 40 \mathrm{~g} /$ day; for women 0.1 - $19.9 \mathrm{~g} /$ day and $\geq 20 \mathrm{~g} /$ day
$\|$ only for women aged $\geq 50$ years ( $n=606$ ) with no current use of OC; \# only for women aged $<50$ years ( $n=413$ ) with no current HRT Weights: cases $=1$; non-cases $=1 /$ sfrac with sfrac $=$ Subcohort/full cohort without cases for each sex and survey BP: blood pressure, DM: diabetes mellitus, MI: myocardial infarction, CRP: C-reactive protein, TC: total cholesterol, HDL-C: high density lipoprotein cholesterol, HRT: hormone replacement therapy, OC: oral contraceptives

Table II. Hazard ratios for the risk of developing type 2 diabetes mellitus according to baseline levels of CRP for men and women

|  | Men |  |  |  | Women |  |  |  | Pfor sex <br> interaction |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Tertiles of CRP |  |  | $\begin{aligned} & \hline P \text { for } \\ & \text { trend } \end{aligned}$ | Tertiles of CRP |  |  | $\begin{aligned} & \hline P \text { for } \\ & \text { trend } \end{aligned}$ |  |
|  | T1 | T2 | T3 |  | T1 | T2 | T3 |  |  |
| Model 4* + antihypertensive medication |  |  |  |  |  |  |  |  |  |
| $\begin{aligned} & \text { HR } \\ & (95 \% \mathrm{Cl}) \end{aligned}$ | 1.0 | $\begin{gathered} 1.19 \\ (0.81-1.77) \end{gathered}$ | $\begin{gathered} 1.07 \\ (0.70-1.63) \end{gathered}$ | 0.897 | 1.0 | $\begin{gathered} 1.99 \\ (1.08-3.67) \end{gathered}$ | $\begin{gathered} 2.63 \\ (1.41-4.91) \end{gathered}$ | 0.017 | 0.101 |
| Model 4* + lipid-lowering medication |  |  |  |  |  |  |  |  |  |
| HR <br> (95\% CI) |  | $\begin{gathered} 1.23 \\ (0.83-1.82) \end{gathered}$ | $\begin{gathered} 1.13 \\ (0.74-1.73) \end{gathered}$ | 0.903 | 1.0 | $\begin{gathered} 2.07 \\ (1.12-3.82) \end{gathered}$ | $\begin{gathered} 2.80 \\ (1.50-5.22) \end{gathered}$ | 0.007 | 0.067 |
| Model 4 * <br> HR <br> (95\% CI) | ntra | ves + use of | RT | -- | 1.0 | $\begin{gathered} 2.12 \\ (1.15-3.92) \end{gathered}$ | $\begin{gathered} 2.88 \\ (1.52-5.46) \end{gathered}$ | 0.010 |  |
| Model 4* after exclusion of subjects with $\mathrm{CHD}^{\dagger}$ |  |  |  |  |  |  |  |  |  |
| HR <br> (95\% CI) |  | $\begin{gathered} 1.12 \\ (0.72-1.74) \end{gathered}$ | $\begin{gathered} 0.92 \\ (0.56-1.51) \end{gathered}$ | 0.486 | 1.0 | $\begin{gathered} 2.30 \\ (1.18-4.49) \end{gathered}$ | $\begin{gathered} 3.02 \\ (1.53-5.94) \end{gathered}$ | 0.014 | 0.034 |
| Model $4^{*}$ after exclusion of subjects with follow-up $\leq 5$ years ${ }^{\ddagger}$ |  |  |  |  |  |  |  |  |  |
| $\begin{aligned} & \text { HR } \\ & \text { (95\% CI) } \end{aligned}$ | 1.0 | $\begin{gathered} 1.21 \\ (0.77-1.91) \end{gathered}$ | $\begin{gathered} 0.93 \\ (0.56-1.54) \end{gathered}$ | 0.436 | 1.0 | $\begin{gathered} 2.01 \\ (1.02-3.95) \end{gathered}$ | $\begin{gathered} 2.56 \\ (1.26-5.21) \end{gathered}$ | 0.043 | 0.124 |
| Model $4^{*}$ after restriction of follow up to $\leq 5$ years ${ }^{\S}$ |  |  |  |  |  |  |  |  |  |
| $\begin{aligned} & \text { HR } \\ & \text { (95\% CI) } \end{aligned}$ | 1.0 | $\begin{gathered} 1.25 \\ (0.66-2.40) \end{gathered}$ | $\begin{gathered} 1.45 \\ (0.72-2.94) \end{gathered}$ | 0.376 | 1.0 | $\begin{gathered} 2.31 \\ (0.63-8.51) \end{gathered}$ | $\begin{gathered} 3.14 \\ (0.88-11.13) \end{gathered}$ | 0.149 | 0.261 |

Table II. continued
Hazard ratios were estimated by Cox proportional hazard model. Correction for standard errors was made by the SAS macro ROBPHREG using the method by Barlow. Tertiles of the weighted distributions in the subcohort, stratified by sex, were used.
*Model 4: adjusted for age and survey and lifestyle factors i.e. smoking status (never smoker, former smoker, current smoker), alcohol consumption ( $0,0.1-39.9, \geq 40 \mathrm{~g} / \mathrm{d}$ for men; $0,0.1-19.9, \geq 20 \mathrm{~g} / \mathrm{d}$ for women) and physical activity (inactive, active), BMI, systolic blood pressure, TC/HDL-C and parental history of diabetes (positive, unknown, negative)
Models contained continuous variables unless otherwise indicated.
${ }^{\dagger} n$ after exclusion of CHD (i.e. prevalent myocardial infarction, prevalent stroke, prevalent angina pectoris or incident myocardial infarction): men 1,012 ( 237 cases, 775 non-cases), women 948 ( 195 cases, 753 non-cases)
$\ddagger$ n after exclusion follow-up $\leq 5$ years: men 962 ( 184 cases, 778 non-cases), women 880 ( 146 cases, 734 non-cases)
$\S_{n}$ after restriction of follow-up to $\leq 5$ years: men 1,194 (121 cases, 1,073 non-cases), women 1,031 ( 76 cases, 955 non-cases) HR: hazard ratio, HRT: hormone replacement therapy

Table III. Hazard ratios for the risk of developing type 2 diabetes mellitus according to baseline levels of IL-6 for men and women

|  | Men |  |  |  | Women |  |  |  | $P$ for sex interaction |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Tertiles of IL-6 |  |  | $\begin{aligned} & \hline P \text { for } \\ & \text { trend } \end{aligned}$ | Tertiles of IL-6 |  |  | $P$ for trend |  |
|  | T1 | T2 | T3 |  | T1 | T2 | T3 |  |  |
| Model 4* + antihypertensive medication |  |  |  |  |  |  |  |  |  |
| $\begin{aligned} & \text { HR } \\ & \text { (95\% CI) } \end{aligned}$ |  | $\begin{gathered} 1.22 \\ (0.83-1.81) \end{gathered}$ | $\begin{gathered} 1.59 \\ (1.09-2.31) \end{gathered}$ | 0.018 | 1.0 | $\begin{gathered} 1.54 \\ (0.88-2.67) \end{gathered}$ | $\begin{gathered} 2.08 \\ (1.21-3.55) \end{gathered}$ | 0.009 | 0.746 |
| Model 4* + lipid-lowering medication |  |  |  |  |  |  |  |  |  |
| $\begin{aligned} & \text { HR } \\ & \text { (95\% CI) } \end{aligned}$ |  | $\begin{gathered} 1.20 \\ (0.81-1.78) \end{gathered}$ | $\begin{gathered} 1.56 \\ (1.08-2.28) \end{gathered}$ | 0.021 | 1.0 | $\begin{gathered} 1.41 \\ (0.82-2.42) \end{gathered}$ | $\begin{gathered} 2.10 \\ (1.24-3.54) \end{gathered}$ | 0.004 | 0.781 |
| Model 4* + use of oral contraceptives and use of HRT |  |  |  |  |  |  |  |  |  |
| $\begin{aligned} & \text { HR } \\ & \text { (95\% CI) } \end{aligned}$ |  | -- | -- | -- | 1.0 | $\begin{gathered} 1.39 \\ (0.81-2.38) \end{gathered}$ | $\begin{gathered} 2.08 \\ (1.23-3.50) \end{gathered}$ | 0.005 | -- |
| Model 4* after exclusion of subjects with $\mathrm{CHD}^{\dagger}$ |  |  |  |  |  |  |  |  |  |
| $\begin{aligned} & \text { HR } \\ & \text { (95\% CI) } \end{aligned}$ |  | $\begin{gathered} 1.32 \\ (0.86-2.02) \end{gathered}$ | $\begin{gathered} 1.33 \\ (0.87-2.04) \end{gathered}$ | 0.296 | 1.0 | $\begin{gathered} 1.43 \\ (0.79-2.57) \end{gathered}$ | $\begin{gathered} 2.16 \\ (1.22-3.79) \end{gathered}$ | 0.006 | 0.532 |
| Model 4* after exclusion of subjects with follow-up $\leq 5$ years ${ }^{\ddagger}$ |  |  |  |  |  |  |  |  |  |
| $\begin{aligned} & \text { HR } \\ & \text { (95\% CI) } \end{aligned}$ |  | $\begin{gathered} 1.21 \\ (0.77-1.90) \end{gathered}$ | $\begin{gathered} 1.44 \\ (0.93-2.25) \end{gathered}$ | 0.119 | 1.0 | $\begin{gathered} 1.70 \\ (0.91-3.15) \end{gathered}$ | $\begin{gathered} 2.28 \\ (1.23-4.22) \end{gathered}$ | 0.011 | 0.608 |
| Model 4* after restriction of follow up to $\leq 5$ years ${ }^{\S}$ |  |  |  |  |  |  |  |  |  |
| $\begin{aligned} & \text { HR } \\ & \text { (95\% CI) } \end{aligned}$ | 1.0 | $\begin{gathered} 1.27 \\ (0.67-2.43) \end{gathered}$ | $\begin{gathered} 1.82 \\ (1.00-3.31) \end{gathered}$ | 0.051 | 1.0 | $\begin{gathered} 0.78 \\ (0.31-1.95) \end{gathered}$ | $\begin{gathered} 1.49 \\ (0.65-3.44) \end{gathered}$ | 0.153 | 0.938 |

Table III. continued
Hazard ratios were estimated by Cox proportional hazard model. Correction for standard errors was made by the SAS macro ROBPHREG using the method by Barlow. Tertiles of the weighted distributions in the subcohort, stratified by sex, were used.
*Model 4: adjusted for age and survey and lifestyle factors i.e. smoking status (never smoker, former smoker, current smoker), alcohol consumption ( $0,0.1-39.9, \geq 40 \mathrm{~g} / \mathrm{d}$ for men; $0,0.1-19.9, \geq 20 \mathrm{~g} / \mathrm{d}$ for women) and physical activity (inactive, active), BMI, systolic blood pressure, TC/HDL-C and parental history of diabetes (positive, unknown, negative)
Models contained continuous variables unless otherwise indicated.
${ }^{\dagger} n$ after exclusion of CHD (i.e. prevalent myocardial infarction, prevalent stroke, prevalent angina pectoris or incident myocardial infarction): m en 1,012 ( 237 cases, 775 non-cases), women 948 ( 195 cases, 753 non-cases)
$\ddagger$ n after exclusion follow-up $\leq 5$ years: men 962 ( 184 cases, 778 non-cases), women 880 ( 146 cases, 734 non-cases)
$\S_{n}$ after restriction of follow-up to $\leq 5$ years: men 1,194 (121 cases, 1,073 non-cases), women 1,031 ( 76 cases, 955 non-cases) HR: hazard ratio, HRT: hormone replacement therapy

Table IV. Hazard ratios for the risk of developing type 2 diabetes mellitus according to baseline levels of CRP and IL-6 for men and women stratified by BMI and smoking status

|  | Men |  |  |  | Women |  |  |  | P for sex interaction |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Tertiles of CRP |  |  | $P$ for trend | Tertiles of CRP |  |  | P for trend |  |
|  | T1 | T2 | T3 |  | T1 | T2 | T3 |  |  |
| Model 4* <br> HR <br> (95\% CI) | $1.0$ | $\begin{gathered} 1.25 \\ (0.78-2.01) \end{gathered}$ | $\begin{gathered} 1.81 \\ (1.13-2.90) \end{gathered}$ | 0.014 | 1.0 | $\begin{gathered} 2.18 \\ (1.12-4.24) \end{gathered}$ | $\begin{gathered} 3.70 \\ (1.85-7.39) \end{gathered}$ | 0.001 | 0.349 |
| $\begin{aligned} & \text { Model } 4^{*} \\ & \text { HR } \\ & (95 \% \mathrm{CI}) \end{aligned}$ | $1.0$ | $\begin{gathered} 1.61 \\ (0.56-4.63) \\ \hline \end{gathered}$ | $\begin{gathered} 0.93 \\ (0.32-2.70) \\ \hline \end{gathered}$ | 0.233 | 1.0 | $\begin{gathered} 2.69 \\ (0.50-14.66) \\ \hline \end{gathered}$ | $\begin{gathered} 4.46 \\ (0.90-22.19) \\ \hline \end{gathered}$ | 0.018 | 0.022 |
| Model 4* <br> HR (95\% CI) | $\begin{array}{r} 5 \text { anc } \\ 10 \end{array}$ | $\begin{gathered} \text {-smokers } \\ 1.03 \\ (0.65-1.61) \end{gathered}$ | $\begin{gathered} 0.95 \\ (0.57-1.57) \end{gathered}$ | 0.761 | 1.0 | $\begin{gathered} 1.94 \\ (1.00-3.78) \end{gathered}$ | $\begin{gathered} 2.69 \\ (1.36-5.33) \end{gathered}$ | 0.018 | 0.074 |
| Model 4* <br> HR (95\% CI) | kers $1.0$ | $\begin{gathered} 2.05 \\ (0.88-4.78) \\ \hline \end{gathered}$ | $\begin{gathered} 1.77 \\ (0.74-4.21) \\ \hline \end{gathered}$ | 0.623 | 1.0 | $\begin{gathered} 1.59 \\ (0.36-7.07) \\ \hline \end{gathered}$ | $\begin{gathered} 1.77 \\ (0.44-7.17) \\ \hline \end{gathered}$ | 0.591 | 0.727 |
|  |  | Tertiles of |  | $P$ for |  | Tertiles of |  | $P$ for | $P$ for sex |
|  | T1 | T2 | T3 | trend | T1 | T2 | T3 | trend | interaction |
| $\begin{aligned} & \text { Model } 4 \text { * } \\ & \text { HR } \\ & (95 \% \mathrm{CI}) \end{aligned}$ | $1.0$ | $\begin{gathered} 1.35 \\ (0.84-2.17) \end{gathered}$ | $\begin{gathered} 2.16 \\ (1.38-3.36) \end{gathered}$ | 0.001 | 1.0 | $\begin{gathered} 1.27 \\ (0.68-2.37) \end{gathered}$ | $\begin{gathered} 1.97 \\ (1.03-3.74) \end{gathered}$ | 0.033 | 0.788 |
| $\begin{aligned} & \text { Model 4*: } \\ & \text { HR } \\ & (95 \% \mathrm{CI}) \end{aligned}$ | $1.0$ | $\begin{gathered} 0.88 \\ (0.42-1.83) \\ \hline \end{gathered}$ | $\begin{gathered} 1.21 \\ (0.58-2.53) \\ \hline \end{gathered}$ | 0.414 | 1.0 | $\begin{gathered} 1.91 \\ (0.70-5.24) \\ \hline \end{gathered}$ | $\begin{gathered} 3.67 \\ (1.49-9.06) \\ \hline \end{gathered}$ | 0.002 | 0.243 |
| Model 4* <br> HR (95\% CI) | $\begin{gathered} s \text { anc } \\ 1.0 \end{gathered}$ | $\begin{gathered} \text {-smokers } \\ 1.12 \\ (0.70-1.79) \end{gathered}$ | $\begin{gathered} 1.54 \\ (0.98-2.44) \end{gathered}$ | 0.059 | 1.0 | $\begin{gathered} 1.54 \\ (0.85-2.80) \end{gathered}$ | $\begin{gathered} 2.18 \\ (1.24-3.83) \end{gathered}$ | 0.007 | 0.547 |
| Model $4^{*}$ <br> HR (95\% CI) | kers | $\begin{gathered} 1.66 \\ (0.75-3.68) \end{gathered}$ | $\begin{gathered} 1.93 \\ (0.90-4.11) \\ \hline \end{gathered}$ | 0.162 | 1.0 | $\begin{gathered} 0.80 \\ (0.23-2.82) \\ \hline \end{gathered}$ | $\begin{gathered} 1.02 \\ (0.30-3.51) \\ \hline \end{gathered}$ | 0.840 | 0.742 |

Table IV. continued
Hazard ratios (HRs) were estimated by Cox proportional hazards model. Correction for standard errors was made by the SAS macro ROBPHREG using the method by Barlow. Tertiles of the weighted distributions in the subcohort, stratified by sex, were used.
*Model 4: adjusted for age and survey and lifestyle factors i.e. smoking status (never smoker, former smoker, current smoker), alcohol consumption ( $0,0.1-39.9, \geq 40 \mathrm{~g} / \mathrm{d}$ for men; $0,0.1-19.9, \geq 20 \mathrm{~g} / \mathrm{d}$ for women) and physical activity (inactive, active), BMI, systolic blood pressure, TC/HDL-C and parental history of diabetes (positive, unknown, negative)
Models contained continuous variables unless otherwise indicated.

